Shalby Ltd Q1 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 15 Jul 2026 | Healthcare Services | Market Cap: ₹1.7K Cr
Shalby MedTech's standalone revenue for Q1 FY '26 grew 271% YoY to INR18.24 crores; consolidated revenue up 74.2% YoY to INR30.8 crores. Shalby Limited expects double-digit consolidated top-line growth of around 12% to 15% for FY '26.
From Shalby Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹153
Market Cap
₹1.7K Cr
P/E Ratio
42.0
How does Shalby Ltd rank in Healthcare Services?
Compare Shalby Ltd against every Healthcare Services company this quarter on revenue, margins and earnings-call signals.
Shalby Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹287 Cr, net profit ₹18 Cr.
Full financials →📊 Revenue & Sales Performance
- →Shalby MedTech's standalone revenue for Q1 FY '26 grew 271% YoY to INR18.24 crores; consolidated revenue up 74.2% YoY to INR30.8 crores.
- →Implant component sales increased by 228.4% YoY (9,317 units) in standalone and 65.4% YoY (14,076 units) consolidated in Q1 FY '26.
- →Expect double-digit top-line growth of around 12%-15% for the full FY '26.
- →Planned global launch of 2 new products in FY '26 and expansion into 4-5 new countries to increase market presence.
- →Focus on increasing market share in key markets like the US, India, Indonesia, and Japan through partnerships and training.
- →The orthopedic implant business aims to reach $100 million revenue in 4-5 years, overcoming supply chain challenges.
- →Domestic and international hospital businesses expected to grow, with occupancy rates improving towards 50%+ in FY '26.
- →Long-term focus on building the orthopedic business first before expanding into other medical devices like oncology, ophthalmology, and dental.
📈 Profitability & Margins
- →Shalby Limited expects double-digit consolidated top-line growth of around 12% to 15% for FY '26.
- →EBITDA margins are anticipated to improve in line with revenue growth.
- →Implant business to see single-digit EBITDA margins in current and next year, improving to 20%-25% over 4 to 5 years.
- →Implant business revenue target of $100 million is maintained, expected to be achieved over 4-5 years due to supply chain and product development timelines.
- →Implant business expected to eventually contribute around 25% of overall profits, but not immediately.
- →Mature hospitals (10+ years) highly profitable with ~36% EBITDA margins; 5-10 year old hospitals expected to show higher growth momentum (20%+ growth).
- →Occupancy expected to improve from ~45% currently to above 50% during FY '26, supporting revenue growth.
- →Continued investments in doctors and operational efficiencies to drive earnings growth.
🏗️ Capital Expenditure Plans
- →Mumbai hospital project: Received Charity Commission approval; awaiting lease formalities and handover from the trust. Construction expected to start after regulatory approvals, with a project timeline of 3 to 3.5 years from handover.
- →Focus on orthopedic business expansion: Current investments targeted at building the orthopedic division, with plans to grow this segment significantly before exploring other medical devices such as oncology, ophthalmology, and dental in the long term.
- →Careful scaling of franchise/lightweight model: Being very selective with hospital partners to maintain quality and brand reputation; no rapid expansion to avoid past issues.
- →Continued investments in implant business: Capital being invested heavily currently, expected to lower in coming quarters as business turns profitable and scales towards a $100 million target over 4-5 years.
💰 Fundraising & Capital Structure
- →There is no explicit mention of any immediate plans for new fundraising through debt or equity in the transcript.
- →Amit Pathak mentions that debt is primarily related to the implant business, which will start becoming profitable in coming quarters, implying lower future capital needs.
- →Interest costs are expected to slightly decrease due to improved profitability and reduced investment requirements in the implant business.
- →No detailed comments on raising funds through equity.
- →No direct remarks about new debt financing or equity issuance for ongoing or future projects such as the Mumbai hospital.
- →The focus appears to be on organic growth and operational improvements rather than external fundraising at this stage.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Shalby Ltd Q1 FY26 results?
Shalby MedTech's standalone revenue for Q1 FY '26 grew 271% YoY to INR18.24 crores; consolidated revenue up 74.2% YoY to INR30.8 crores. Shalby Limited expects double-digit consolidated top-line growth of around 12% to 15% for FY '26.
What is Shalby Ltd share price analysis?
Shalby Ltd currently shows a neutral. The stock trades at a P/E of 42.0 with a market cap of ₹1,652 Cr. Investors should review the full earnings analysis for detailed insights.
Is Shalby Ltd planning capital expenditure?
Mumbai hospital project: Received Charity Commission approval; awaiting lease formalities and handover from the trust.
Keep Shalby Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.